Tubulysin |
| Catalog No.GC37835 |
2차 대사산물의 Tubulysin 계열은 원래 점액박테리아 Archangium geophyra와 Angiococcus disciformis에서 분리되었습니다. 이들 화합물은 다중약물 내성 특성을 갖는 것을 포함하여 많은 암 세포주에 대해 피코몰 범위의 IC50 값을 갖는 강력한 미세소관 불안정화제입니다. 튜불리신은 심각한 독성으로 인해 치료적 유용성이 제한되어 있으므로 튜불리신은 분자 약물 접합체(SMDC) 전달 시스템에 통합하기에 이상적인 후보입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1943604-24-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tubulysin family of secondary metabolites are originally isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. These compounds are potent microtubule destabilizing agents with IC50 values in the picomolar range against many cancer cell lines, including those with multidrug resistant properties. Tubulysins have limited therapeutic utility due to severe toxicity, so Tubulysins are ideal candidates to be incorporated into molecule drug conjugate (SMDC) delivery system[1].
[1]. Leamon CP, et al. Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate. Bioconjug Chem. 2019 Jun 19;30(6):1805-1813.
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *